144 related articles for article (PubMed ID: 16055185)
1. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
Ho AD; Lipp T; Ehninger G; Meyer P; Freund M; Hunstein W
Cancer Treat Rep; 1986 Aug; 70(8):1025-7. PubMed ID: 3460698
[TBL] [Abstract][Full Text] [Related]
3. [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
Tsurumi H; Miura T; Yamada T; Sawada M; Nakamura N; Tomoda T; Takahashi T; Oyama M; Moriwaki H; Muto Y
Rinsho Ketsueki; 1995 Jul; 36(7):657-64. PubMed ID: 7563593
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
Saito K; Furusawa S; Yamada K; Waga K; Aoyagi A; Koike T; Arimura H; Noguchi M; Yamato H; Sakuma H
Rinsho Ketsueki; 1995 Mar; 36(3):165-74. PubMed ID: 7540220
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients.
Tribalto M; Cantonetti M; Catalano G; Del Poeta G; Masi M; Pastore S; Pisani F; Stasi R; Papa G
Haematologica; 1991; 76(5):402-5. PubMed ID: 1806445
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
[TBL] [Abstract][Full Text] [Related]
9. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Koyama S; Itou S; Shibata A
Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
[TBL] [Abstract][Full Text] [Related]
10. [Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Chubachi A; Kuriya S; Narigasawa Y; Meguro K; Endo K; Takami H; Sato S; Sasaki H; Shiga T; Maruyama Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2101-6. PubMed ID: 8607622
[TBL] [Abstract][Full Text] [Related]
11. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Evensen SA; Brinch L; Wisløff F
Tidsskr Nor Laegeforen; 1989 Jun; 109(19-21):2004-6. PubMed ID: 2749689
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
[TBL] [Abstract][Full Text] [Related]
13. ["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
Asou N; Suzushima H; Hamasaki N; Goto J; Hidaka M; Akagi K; Kurisaki H; Sawatari T; Kawano F; Takatsuki K
Rinsho Ketsueki; 1989 Feb; 30(2):169-74. PubMed ID: 2746873
[TBL] [Abstract][Full Text] [Related]
14. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
[TBL] [Abstract][Full Text] [Related]
15. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
Kawada H; Komatsuda M; Masumoto A; Fukuda R; Watanabe S; Yonekura S; Ichikawa Y; Nagao T; Arimori S
Rinsho Ketsueki; 1993 May; 34(5):667-9. PubMed ID: 8315839
[TBL] [Abstract][Full Text] [Related]
16. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
[TBL] [Abstract][Full Text] [Related]
17. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
Semin Hematol; 1991 Jul; 28(3 Suppl 4):35-8. PubMed ID: 1780750
[No Abstract] [Full Text] [Related]
18. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
Visani G; Petti MC; Cenacchi A; Manfroi S; Tosi P; Spadea A; Latagliata R; Amadori S; Mandelli F; Tura S
Leuk Lymphoma; 1995 Nov; 19(5-6):447-51. PubMed ID: 8590845
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Lazzarino M; Morra E; Alessandrino EP; Orlandi E; Pagnucco G; Merante S; Bernasconi P; Inverardi D; Bonfichi M; Bernasconi C
Eur J Haematol; 1989 Nov; 43(5):411-6. PubMed ID: 2612614
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia.
Björkholm M; Björnsdottir J; Stenke L; Grimfors G
Oncology; 1990; 47(2):112-4. PubMed ID: 2314823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
